Gliomatosis Cerebri
Symptoms, Doctors, Treatments, Advances & More

Gliomatosis Cerebri Overview

Save information for later
Sign Up

Learn About Gliomatosis Cerebri

View Main Condition: Brain Tumor

What is the definition of Gliomatosis Cerebri?
Gliomatosis cerebri is a type of malignant (cancerous) brain tumor called a glioblastoma that develops from a specific type of brain cell called an astrocyte. It involves at least three sections (lobes) within the main part of the brain (cerebrum). It may also affect both sides of the cerebrum as well as the nerve cells within the brain (grey matter). There are two types of Gliomatosis cerebri. Type 1 (classic form) is characterized by scattered and widespread tumor cells and no apparent mass or tumor, while type 2 has similar characteristics in addition to a detectable mass or tumor. Signs and symptoms of Gliomatosis cerebri may include personality changes, memory disturbance, headaches, and seizures.
What are the alternative names for Gliomatosis Cerebri?
  • Gliomatosis cerebri
Who are the top Gliomatosis Cerebri Local Doctors?
Elite in Gliomatosis Cerebri
Dr. Lewis E. Sulman
Radiation Oncology
Elite in Gliomatosis Cerebri
Dr. Lewis E. Sulman
Radiation Oncology
20 Duke Medicine Cir, 
Durham, NC 
919-668-5640
Languages Spoken:
English
See accepted insurances

Lewis Sulman is a Radiation Oncologist in Durham, North Carolina. Dr. Sulman is rated as an Elite provider by MediFind in the treatment of Gliomatosis Cerebri. His top areas of expertise are Astrocytoma, Glioma, Glioblastoma, Gliomatosis Cerebri, and Gamma Knife Radiosurgery.

Patrick Y. Wen
Elite in Gliomatosis Cerebri
Dr. Patrick Y. Wen
Neurology
Elite in Gliomatosis Cerebri
Dr. Patrick Y. Wen
Neurology

Dana-Farber Cancer Institute, Center For Neuro-Oncology

450 Brookline Avenue, 
Boston, MA 
617-632-2166
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Patrick Wen is a Neurologist in Boston, Massachusetts. Dr. Wen is rated as an Elite provider by MediFind in the treatment of Gliomatosis Cerebri. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

 
 
 
 
Learn about our expert tiers
Learn More
Roger Stupp
Elite in Gliomatosis Cerebri
Dr. Roger Stupp
Hematology Oncology | Neurology | Hematology
Elite in Gliomatosis Cerebri
Dr. Roger Stupp
Hematology Oncology | Neurology | Hematology
675 N St Clair St Ste 20-100, Galter Pavilion, 
Chicago, IL 
312-695-4360
Experience:
39+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Roger Stupp is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Dr. Stupp has been practicing medicine for over 39 years and is rated as an Elite provider by MediFind in the treatment of Gliomatosis Cerebri. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Gliomatosis Cerebri.

View All Doctors
What are the latest Gliomatosis Cerebri Clinical Trials?
A Phase 2 Study of Erdafitinib in Patients With Recurrent or Progressive IDH-Wild Type Glioma With an FGFR-TACC Gene Fusion
A Phase 2 Study of Erdafitinib in Patients With Recurrent or Progressive IDH-Wild Type Glioma With an FGFR-TACC Gene Fusion
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Phase: Phase 2

Summary: This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals tumor c...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 1 Study of Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells in Adult Participants With EGFRvIII+ Glioblastoma
Phase 1 Study of Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells in Adult Participants With EGFRvIII+ Glioblastoma
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Biological, Drug, Procedure
Study Phase: Phase 1

Summary: This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so the CAR T cells will atta...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center